CYBERMED NEWS - Higher Medical Scientifc Information and Research

PHARMACOVIGILANCE

One in three new drugs have serious—and sometimes deadly—safety issues

Written by CYBERMED NEWS
facebook Share on Facebook

There's something seriously wrong with our drug approval processes. One in three drugs that pass all the usual checks before being given a licence are unsafe, and are causing serious—and sometimes deadly—health reactions in patients.

 

The safety concerns are so serious that the drug either is pulled from the market, or the drug regulator is forced to issue special warnings that the drug can have fatal effects.

 

The dangers of the new drugs often don't come to light until four years after they have been licensed, which means that many thousands of patients may have been affected. But in every case, doctors and patients believed the drugs were safe because they had passed all the usual tests for safety and effectiveness.

 

Researchers from the Brigham and Women's Hospital in Boston uncovered the failures in safety testing when they looked at the track record of 222 new drugs that had been passed as safe by America's drug regulator, the Food and Drug Administration (FDA), between 2001 and 2010. One in three of these had a 'safety event', the researchers discovered, which included three drugs which were withdrawn because they were so dangerous, 61 had 'boxed warnings'—the FDA's most serious alert before a drug is taken off the market, and means the drug may be a killer—and 59 had their safety questioned.

 

"These safety risks emerge, on average, four years after approval. This means that many patients are exposed to these medications before the risks become clear," said lead researcher Nicholas Downing.

 

The drugs with potentially fatal effects included SSRI (selective serotonin reuptake inhibitor) antidepressants, antipsychotics and a new class of drugs that treats auto-immune problems.

 

http://wddty.com/news/2017/05/one-in-three-new-drugs-have-serious-and-sometimes-deadly-safety-issues.html?utm_source=Boomtrain&utm_medium=email&utm_campaign=enews_16052017&bt_ee=xVVAohZVF2XeJEY9hcrCpJDcsCCoNUnUW+nimNkL3EU=&bt_ts=1494933506211


Related Articles
Category:

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.